[{"NetIncomeLoss_4_FY_USD":-58574000.0,"GoodwillImpairmentLoss_4_FY_USD":0.0,"AccruedLiabilitiesCurrentAndNoncurrent_0_FY_USD":29691000.0,"WeightedAverageNumberOfSharesIssuedBasic_4_FY_shares":110841000.0,"PaymentsToAcquireInvestments_4_FY_USD":58555000.0,"StockIssuedDuringPeriodValueNewIssues_4_FY_USD":6963000.0,"NetCashProvidedByUsedInInvestingActivities_4_FY_USD":380756000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_FY_USD":15700000.0,"ValuationAllowanceDeferredTaxAssetChangeInAmount_4_FY_USD":20400000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_FY_USD":500000.0,"InterestPaidNet_4_FY_USD":17353000.0,"AccruedLiabilitiesCurrent_0_FY_USD":29691000.0,"CommitmentsAndContingencies_0_FY_USD":null,"RepaymentsOfLongTermDebt_4_FY_USD":216580000.0,"GeneralAndAdministrativeExpense_4_FY_USD":47230000.0,"PreferredStockSharesOutstanding_0_FY_shares":0.0,"DeferredIncomeTaxLiabilities_0_FY_USD":0.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_FY_USD":-6000.0,"IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_4_FY_USD":0.0,"IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4_FY_USD":-12300000.0,"AssetsCurrent_0_FY_USD":157719000.0,"DeferredTaxAssetsTaxCreditCarryforwardsResearch_0_FY_USD":29304000.0,"ConversionOfStockAmountIssued1_4_FY_USD":15714000.0,"Land_0_FY_USD":2700000.0,"TreasuryStockValue_0_FY_USD":4843000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_4_FY_USD":2000.0,"CurrentStateAndLocalTaxExpenseBenefit_4_FY_USD":-269000.0,"AvailableForSaleSecurities_0_FY_USD":26012000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4_FY_shares":11113054.0,"DeferredTaxAssetsOperatingLossCarryforwards_0_FY_USD":201610000.0,"TreasuryStockShares_0_FY_shares":793000.0,"CostOfGoodsAndServicesSold_4_FY_USD":1929000.0,"IncomeTaxReconciliationOtherAdjustments_4_FY_USD":157000.0,"ProceedsFromIssuanceOfLongTermDebt_4_FY_USD":0.0,"EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_4_FY_USD":1777000.0,"LongTermDebtCurrent_0_FY_USD":11646000.0,"SaleOfStockConsiderationReceivedPerTransaction_4_FY_USD":63007000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4_FY_shares":0.0,"AvailableForSaleSecuritiesAmortizedCost_0_FY_USD":26018000.0,"DeferredTaxLiabilities_0_FY_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4_FY_USD":-90000.0,"DefinedContributionPlanCostRecognized_4_FY_USD":900000.0,"TreasuryStockValueAcquiredCostMethod_4_FY_USD":1026000.0,"InventoryBuildingsAndImprovements_0_FY_USD":7900000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4_FY_USD":-20969000.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_FY_USD":0.0,"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4_FY_USD":15714000.0,"Revenues_4_FY_USD":23995000.0,"CommonStockValue_0_FY_USD":142000.0,"IncreaseDecreaseInDeferredRevenue_4_FY_USD":0.0,"OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0_FY_USD":0.0,"AccountsReceivableNetCurrent_0_FY_USD":395000.0,"OtherNonoperatingIncomeExpense_4_FY_USD":2767000.0,"GainsLossesOnExtinguishmentOfDebt_4_FY_USD":1003000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":110841000.0,"OperatingLeasesFutureMinimumPaymentsDueThereafter_0_FY_USD":0.0,"EarningsPerShareBasic_4_FY_USD":-0.53,"ResearchAndDevelopmentExpense_4_FY_USD":153621000.0,"ShortTermInvestments_0_FY_USD":26012000.0,"DebtInstrumentInterestRateStatedPercentage_0_FY_pure":0.09,"RoyaltyIncomeNonoperating_4_FY_USD":558000.0,"DepreciationDepletionAndAmortization_4_FY_USD":2934000.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_4_FY_USD":90151000.0,"Liabilities_0_FY_USD":47417000.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_4_FY_USD":268000000.0,"CashAndCashEquivalentsAtCarryingValue_0_FY_USD":126263000.0,"ShortTermLeaseCommitmentAmount_0_FY_USD":553000.0,"OtherAssetsNoncurrent_0_FY_USD":1231000.0,"ComprehensiveIncomeNetOfTax_4_FY_USD":-58664000.0,"FiniteLivedIntangibleAssetsFairValueDisclosure_0_FY_USD":18500000.0,"IncreaseDecreaseInInventories_4_FY_USD":-345000.0,"OtherAssetsCurrent_0_FY_USD":5049000.0,"SharesIssuedPricePerShare_0_FY_USD":3.2,"DeferredTaxAssetsOther_0_FY_USD":844000.0,"AvailableForSaleSecuritiesCurrent_0_FY_USD":26012000.0,"UnamortizedDebtIssuanceExpense_0_FY_USD":100000.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4_FY_USD":1600000.0,"RealizedInvestmentGainsLosses_4_FY_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_4_FY_USD":-147636000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_FY_USD":11000.0,"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0_FY_USD":3437000.0,"ConvertibleDebt_0_FY_USD":11600000.0,"Assets_0_FY_USD":203788000.0,"OperatingLeaseRightOfUseAsset_0_FY_USD":1200000.0,"NetCashProvidedByUsedInOperatingActivities_4_FY_USD":-142969000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4_FY_USD":13274000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_4_FY_USD":11013000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4_FY_USD":-58574000.0,"LongTermDebtAndCapitalLeaseObligations_0_FY_USD":611000.0,"Goodwill_0_FY_USD":44543000.0,"OperatingLossCarryforwards_0_FY_USD":918100000.0,"IncrementalCommonSharesAttributableToConversionOfDebtSecurities_4_FY_shares":0.0,"OperatingLeasesFutureMinimumPaymentsDueInFourYears_0_FY_USD":0.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_FY_USD":5815000.0,"ProceedsFromSaleOfBuildings_4_FY_USD":11900000.0,"DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_4_FY_USD":-58574000.0,"OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0_FY_USD":645000.0,"DebtInstrumentFairValue_0_FY_USD":9200000.0,"InvestmentsFairValueDisclosure_0_FY_USD":152275000.0,"EarningsPerShareDiluted_4_FY_USD":-0.53,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0_FY_shares":11165885.0,"MortgageLoansOnRealEstate_0_FY_USD":11000000.0,"GainLossOnDispositionOfAssets_4_FY_USD":707000.0,"LiabilitiesCurrent_0_FY_USD":46806000.0,"PropertyPlantAndEquipmentNet_0_FY_USD":295000.0,"DeferredTaxAssetsInProcessResearchAndDevelopment_0_FY_USD":47075000.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_FY_USD":0.0,"PreferredStockSharesIssued_0_FY_shares":0.0,"NumberOfOperatingSegments_4_FY_segment":1.0,"OtherIntangibleAssetsNet_0_FY_USD":0.0,"AdditionalPaidInCapital_0_FY_USD":1561096000.0,"IncreaseDecreaseInOtherOperatingAssets_4_FY_USD":-424000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4_FY_USD":3200000.0,"OtherAccruedLiabilitiesCurrent_0_FY_USD":976000.0,"LongTermDebtNoncurrent_0_FY_USD":0.0,"SeveranceCosts1_4_FY_USD":5500000.0,"CashAndCashEquivalentsFairValueDisclosure_0_FY_USD":126263000.0,"InterestExpense_4_FY_USD":14544000.0,"EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_4_FY_pure":0.21,"SaleOfStockNumberOfSharesIssuedInTransaction_4_FY_shares":20312500.0,"AccountsPayableCurrent_0_FY_USD":5469000.0,"ProceedsFromConvertibleDebt_4_FY_USD":75800000.0,"DeferredTaxAssetsGross_0_FY_USD":309008000.0,"IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4_FY_USD":-20418000.0,"AssetImpairmentCharges_4_FY_USD":0.0,"DeferredIncomeTaxExpenseBenefit_4_FY_USD":0.0,"PreferredStockValue_0_FY_USD":0.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_FY_USD":5000.0,"DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_4_FY_USD":0.0,"InventoryNet_0_FY_USD":0.0,"PaymentsForRepurchaseOfCommonStock_4_FY_USD":1026000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0_FY_shares":14118789.0,"OperatingIncomeLoss_4_FY_USD":-47800000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_4_FY_USD":23404000.0,"CommonStockSharesAuthorized_0_FY_shares":225000000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4_FY_USD":1948000.0,"ProceedsFromSaleOfProductiveAssets_4_FY_USD":160385000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4_FY_USD":2.35,"CommonStockParOrStatedValuePerShare_0_FY_USD":0.001,"ImpairmentOfRealEstate_4_FY_USD":1600000.0,"ProceedsFromIssuanceOfCommonStock_4_FY_USD":69970000.0,"PreferredStockParOrStatedValuePerShare_0_FY_USD":0.01,"LiabilitiesAndStockholdersEquity_0_FY_USD":203788000.0,"ShareBasedCompensation_4_FY_USD":13274000.0,"PreferredStockSharesAuthorized_0_FY_shares":5000000.0,"DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0_FY_USD":86900000.0,"IncreaseDecreaseInAccountsReceivable_4_FY_USD":-53227000.0,"DebtInstrumentConvertibleConversionPrice1_0_FY_USD":8.442,"RetainedEarningsAccumulatedDeficit_0_FY_USD":-1400018000.0,"OperatingLeasesFutureMinimumPaymentsDueInFiveYears_0_FY_USD":0.0,"DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4_FY_USD":-12200000.0,"AmortizationOfFinancingCostsAndDiscounts_4_FY_USD":1013000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_4_FY_USD":33000.0,"DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0_FY_USD":5651000.0,"PaymentsToAcquirePropertyPlantAndEquipment_4_FY_USD":87000.0,"StockholdersEquity_0_FY_USD":156371000.0,"OperatingLeasesFutureMinimumPaymentsDueCurrent_0_FY_USD":632000.0,"OtherLiabilitiesNoncurrent_0_FY_USD":611000.0,"ProfitLoss_4_FY_USD":-58574000.0,"OperatingExpenses_4_FY_USD":204380000.0,"OperatingLeaseLiabilityCurrent_0_FY_USD":553000.0,"DeferredTaxLiabilitiesOther_0_FY_USD":0.0,"PropertyPlantAndEquipmentGross_0_FY_USD":6110000.0,"DeferredTaxAssetsValuationAllowance_0_FY_USD":309008000.0,"OperatingLeasesFutureMinimumPaymentsDue_0_FY_USD":1277000.0,"Ticker":"LXRX","CIK":"1062822","name":"LEXICON PHARMACEUTICALS, INC.","OfficialName":"Lexicon Pharmaceuticals Inc. Common Stock","form":"10-K","period":"20201231","fy":"2020.0","fp":"FY","qtrs":"4","uom":"USD","footnote":"nan","Market Cap":"332097683.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210312"}]